First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap.

Immunotherapy · 2025 · PMC12427484 · PMID 40910565

Europe PMC DOI

hedged sentence

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

showed a trendp = 0.067so close (0.05 < p ≤ 0.1)

Univariable and multivariable analysis for DCR (supplemental tables S2 and S3) None of the variables were significantly associated with DCR on univariable and multivariable logistic regression analysis, though the presence of extra-thoracic metastases showed a trend (OR = 0.37, p = 0.067). 3.4.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.